Initial absolute monocyte count as an immune biomarker for clinical response in acute myeloid leukemia with monocytic differentiation.
Ahmed EmbabyAyman FathyMohammad Al-AkkadAhmad BarakaTaiseer IbrahimNahla ZidanMohamed RefaatHaitham ElsheikhPublished in: Journal of the Egyptian National Cancer Institute (2020)
Initial AMC was found to be an independent prognostic immune biomarker for treatment response in AML patients with monocytic differentiation. However, it did not appear as an independent predictor of survival in a multivariate analysis.